Bobak R. Azamian, the President/CEO and Board Chair of $TARS, sold 557 shares of the company on 12-24-2025 for an estimated $46,531. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.1% of their shares of this class of stock. Following this trade, they now own 857,991 shares of this class of $TARS stock.
$TARS Insider Trading Activity
$TARS insiders have traded $TARS stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $TARS stock by insiders over the last 6 months:
- WILLIAM J PHD LINK has made 0 purchases and 6 sales selling 50,062 shares for an estimated $3,410,289.
- BOBAK R. AZAMIAN (President/CEO and Board Chair) has made 0 purchases and 4 sales selling 18,000 shares for an estimated $1,127,309.
- DIANNE C. WHITFIELD (Chief Human Resources Officer) sold 7,397 shares for an estimated $592,499
- ELIZABETH YEU LIN (Chief Medical Officer) sold 2,078 shares for an estimated $165,201
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TARS Hedge Fund Activity
We have seen 100 institutional investors add shares of $TARS stock to their portfolio, and 110 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 1,250,000 shares (+71.4%) to their portfolio in Q3 2025, for an estimated $74,287,500
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 543,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $32,270,490
- LOOMIS SAYLES & CO L P added 389,901 shares (+inf%) to their portfolio in Q3 2025, for an estimated $23,171,816
- TORONTO DOMINION BANK removed 384,379 shares (-38.4%) from their portfolio in Q3 2025, for an estimated $22,843,643
- JANUS HENDERSON GROUP PLC removed 367,948 shares (-20.4%) from their portfolio in Q3 2025, for an estimated $21,867,149
- J. GOLDMAN & CO LP removed 320,257 shares (-87.8%) from their portfolio in Q3 2025, for an estimated $19,032,873
- PARADIGM BIOCAPITAL ADVISORS LP removed 310,401 shares (-10.4%) from their portfolio in Q3 2025, for an estimated $18,447,131
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TARS Analyst Ratings
Wall Street analysts have issued reports on $TARS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 11/20/2025
To track analyst ratings and price targets for $TARS, check out Quiver Quantitative's $TARS forecast page.
$TARS Price Targets
Multiple analysts have issued price targets for $TARS recently. We have seen 4 analysts offer price targets for $TARS in the last 6 months, with a median target of $94.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $100.0 on 12/09/2025
- Graig Suvannavejh from Mizuho set a target price of $100.0 on 11/20/2025
- Eddie Hickman from Guggenheim set a target price of $87.0 on 11/05/2025
- Matthew Caufield from HC Wainwright & Co. set a target price of $88.0 on 10/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
